share_log

NAMSA, InspireMD Announce Strategic Outsourcing Partnership To Accelerate New Product Development; Terms Not Disclosed

NAMSA, InspireMD Announce Strategic Outsourcing Partnership To Accelerate New Product Development; Terms Not Disclosed

NAMSA和InspirreMD宣布建立战略外包合作伙伴关系以加快新产品开发;条款未披露
Benzinga Real-time News ·  2022/09/08 09:02

NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.

提供全球端到端开发服务的世界领先的医疗技术合同研究组织NAMSA和用于治疗颈动脉疾病和预防中风的CGuard血栓预防系统的开发商InSpireMD公司(纳斯达克代码:NSPR)今天宣布,他们已经达成战略外包合作伙伴关系,以加快医疗设备的开发和商业化。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发